Percutaneous coronary intervention in chronic kidney disease patients

Area of Science:

• Nephrology
• Cardiology
• Cardiovascular Medicine

Background:

• Cardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).
• Effective prevention strategies and therapy utilization are lacking, contributing to the high CVD prevalence in renal dysfunction patients.
• Optimal treatment for ischemic heart disease in ESRD patients awaiting renal transplantation remains controversial.

Purpose of the Study:

• To review and compare the effectiveness of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for ischemic heart disease in ESRD patients before renal transplantation.
• To highlight the challenges and suboptimal outcomes associated with revascularization strategies in this patient population.
• To identify areas for future research in managing CVD in CKD and ESRD patients.

Main Methods:

• Review of existing data and small trials comparing PCI and CABG in ESRD patients.
• Analysis of angiographic success rates, restenosis, revascularization needs, and long-term outcomes.
• Consideration of patient eligibility for surgical intervention and symptom severity.

Main Results:

• PCI demonstrates excellent angiographic success but is linked to increased restenosis and revascularization requirements.
• CABG, despite higher in-hospital morbidity and mortality, offers better long-term results and angina relief.
• Outcomes for both CABG and PCI in ESRD patients are significantly worse compared to the general population.

Conclusions:

• PCI is a viable option for non-surgical candidates or those with disabling angina refractory to medical therapy.
• CABG may provide superior long-term benefits despite initial higher risks.
• Further research is crucial to optimize revascularization strategies and explore adjunctive medical therapies like beta-blockers, statins, and RAAS inhibition in CKD patients.